1. Home
  2. FONR vs BMEA Comparison

FONR vs BMEA Comparison

Compare FONR & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fonar Corporation

FONR

Fonar Corporation

HOLD

Current Price

$18.90

Market Cap

117.3M

Sector

Health Care

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.45

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FONR
BMEA
Founded
1978
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.3M
138.1M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
FONR
BMEA
Price
$18.90
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
41.2K
2.0M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
1.16
N/A
Revenue
$104,351,318.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.28
N/A
Revenue Growth
1.43
N/A
52 Week Low
$12.14
$0.87
52 Week High
$18.88
$3.07

Technical Indicators

Market Signals
Indicator
FONR
BMEA
Relative Strength Index (RSI) 81.21 40.15
Support Level $18.31 $1.22
Resistance Level N/A $1.47
Average True Range (ATR) 0.05 0.16
MACD 0.01 -0.07
Stochastic Oscillator 100.00 1.86

Price Performance

Historical Comparison
FONR
BMEA

About FONR Fonar Corporation

Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: